Treatment futility and success in the context of suspending treatment

My guest for this episode is Professor David Wong from the Department of Ophthalmology and Vision Sciences, University of Toronto and Unity Health Toronto in Toronto, Canada. In this episode, David and I discuss the Vision Academy’s algorithms for suspending treatment for nAMD in the context of treatment futility and success. Our conversation highlights the monitoring considerations and criteria used to define treatment futility and success, and the potential of predictive biomarkers and at-home monitoring to optimize patient follow-up. Important resources, such as the Vision Academy Viewpoint and algorithm on suspending treatment of nAMD in cases of futility, can be found on the website. Or can be downloaded directly from here; view point and slide deck. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. If you enjoyed this episode, SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode! Further information on content in other podcasts in this series can be found here.Speaker disclosures:Professor Anat LoewensteinConsultancy: 4DMT, Abbvie, Alkeus, Annexon, Apellis, Astellas, Bayer health care, Beyeonics, Eyepoint, J & J, NotalVision, Novartis, Ocular Therapeutics, Ocuphire Pharma, Ocuterra, Oculis, Opthea, Oxurion, Roche, Syneos.Professor David Wong Consultancy: Abbvie, Alcon, Apellis, Bayer, Bausch Health, Biogen, Boehringer Ingelheim, Novartis, Ripple Therapeutics, Roche, Topcon, and Zeiss; Research grants: Novartis and Roche.Further information on other studies mentioned in this episode:Wong DT, et al. SUSPENDING TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CASES OF FUTILITY. Retina. 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448759/ June 2026 | PP-PF-OPHT-ALL-0162-1This podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.This podcast series is produced and funded by Bayer Consumer Care AG. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer Consumer Care AG. The activities of the Barometer Program are funded and facilitated by Bayer Consumer Care AG where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer Consumer Care AG. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer Consumer Care AG.